Testagen
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Testagen is a synthetic peptide framed for testicular tissue and natural testosterone support — part of the reproductive/hormone corner of the Khavinson short-peptide bioregulator family, alongside Prostamax. Site tier is Anecdotal (2 studies, 0 human).
What does it do in my body?
Claimed mechanism: like the rest of the Khavinson family, Testagen is proposed to act via gene-promoter binding in testicular tissue, framed as supporting natural testosterone production. There is no Testagen-specific mechanistic study confirming this pathway — the two citations that exist for this peptide are off-target (see below).
How can it help me?
- Where the science stands: Site tier Anecdotal (2 studies, 0 human) — both citations are off-target for the testosterone claim
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-event data exists for Testagen. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and a peptide marketed on a hormone claim it has no human data for is an especially easy target for overselling. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status: Testagen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Testagen, and no human testosterone-outcome data exists to inform a protocol around. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Testagen specifically, let alone for a testosterone-support outcome.
What should I avoid combining — and what's synergistic?
Testagen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
Testagen (Lys-Glu-Asp-Gly / KEDG) is framed for testicular tissue and natural testosterone support — but there is no human testosterone data for it. The two citations attached to it are off-target for that claim entirely. The hormone-support framing is a mechanistic inference, not a measured outcome. Say so plainly.
| Class | Synthetic peptide — Lys-Glu-Asp-Gly (KEDG) |
| Mechanism (one line) | Framed for testicular tissue support and natural testosterone support via the family’s gene-modulation mechanism |
| Evidence base | Site tier Anecdotal (2 studies, 0 human) — both citations are off-target for the testosterone claim |
| Safety record | No AE data specific to Testagen; family-wide mild profile assumed; OHM grade D / provisional |
| Regulatory status | research_only in the US, not FDA-approved |
What it is
Testagen is a synthetic peptide framed for testicular tissue and natural testosterone support — part of the reproductive/hormone corner of the Khavinson short-peptide bioregulator family, alongside Prostamax. Site tier is Anecdotal (2 studies, 0 human).
How it works
Claimed mechanism: like the rest of the Khavinson family, Testagen is proposed to act via gene-promoter binding in testicular tissue, framed as supporting natural testosterone production. There is no Testagen-specific mechanistic study confirming this pathway — the two citations that exist for this peptide are off-target (see below).
What the research shows
The two citations attached to Testagen are off-target for the testosterone claim: a copper-corrosion-inhibition study of the Testagen peptide in saline (Dobriţescu et al. 2025, Molecules, 40807317), and a generic short-peptide nuclear-penetration / DNA-interaction study (Fedoreyeva et al. 2011, 22117547), both.
There is no human testosterone data for Testagen — the hormone-support framing is a mechanistic claim, not a measured outcome. OHM grade: D / provisional.
Real-world protocol
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Testagen, and no human testosterone-outcome data exists to inform a protocol around. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Testagen specifically, let alone for a testosterone-support outcome.
Side effects & management
No adverse-event data exists for Testagen. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and a peptide marketed on a hormone claim it has no human data for is an especially easy target for overselling. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status
Testagen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Sources
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Testagen kept D-provisional / encyclopedia-only.
- 40807317 (Dobriţescu et al. 2025, copper-corrosion inhibition, off-target for testosterone claim); 22117547 (Fedoreyeva et al. 2011, generic nuclear-penetration study).
- Related: Prostamax · the Khavinson bioregulator family.
Sources & references
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Testagen kept D-provisional / encyclopedia-only.
- 40807317 (Dobriţescu et al. 2025, copper-corrosion inhibition, off-target for testosterone claim); 22117547 (Fedoreyeva et al. 2011, generic nuclear-penetration study).
- Related: Prostamax · the Khavinson bioregulator family.